Moderna has joined the world’s major manufacturers of COVID-19 vaccines in the race to investigate the new Omicron variant and adapt their shots to combat the new strain, which has a high number of mutations and appears to spread rapidly.
Speaking on the BBC’s “Andrew Marr Show” on Sunday, Moderna’s chief medical officer Paul Burton said that large quantities of a new and reformulated vaccine to combat the newly identified variant could be available early next year.